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ABSTRACT 
NAFLD is characterised by fatty infiltration of the liver, mostly in the form of triglycerides, which exceeds 5% of 
the liver weight. Insulin resistance impairs the suppression of lipolysis, and this leads to an increased release of free 
fatty acids from adipose tissue so that more are delivered to and taken up by the liver. This excess amount of free 
fatty acids can overload the hepatic mitochondrial beta oxidation system, the major pathway of fatty acid oxidation 
in the liver, leading to the accumulation of fatty acids in the liver. The present hospital-based, observational, 
analytical and comparative study was conducted on 80 subjects including 50 cases of ultrasonographically 
diagnosed NAFLD and 30 age and gender matched healthy subjects as controls. In this study, lipid profile was 
assessed in 50 USG diagnosed cases of NAFLD and 30 controls and the results were analysed statistically. The 
study found a statistically significant change in lipid levels in patients of Non alcoholic fatty liver disease indicating 
hepatic steatosis. In the present study, increased levels of cholesterol, triacylglycerides, LDL, VLDL and decreased 
levels of HDL were found. This study concluded that low fat diet, lifestyle modifications, exercises and yoga could 
be a potential tool to prevent the progression of NAFLD. 
Key words: NAFLD, Cholesterol, LDL, Triacylglycerol, VLDL, HDL. 
 
 
© The Author(s). 2019 Open Access. This work is licensed under a Creative Commons  Attribution. The full terms of this license are available at 
our website and  incorporate the Creative Commons Attribution. https://creativecommons.org/licenses/by/4.0/ 
 
INTRODUCTION 
The liver plays a central role in lipid transport & 
metabolism. A net change in the amount of lipid in the 
liver will occur if there is a change in the balance 
between the liver’s uptake or synthesis of fatty acids 
and the liver’s disposal of fatty acids by oxidation or 
export. [1,2] Non alcoholic fatty liver disease is a 
common hepatic disorder characterized by 
accumulation of fat in the liver parenchyma of the 
patients who do not drink excessive amount of alcohol. 
It is a clinicopathological syndrome characterized by 
wide spectrum of liver damage ranging from benign 
fatty infiltration to steatohepatitis, advanced fibrosis 
and cirrhosis.[3] Fatty liver, or hepatosteatosis, is 
characterized histologically by triglyceride 
accumulation within the cytoplasm of hepatocytes and 
refers to fat accumulation in the liver exceeding 5%–
10% by weight.[4]  
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Abnormalities in fatty acid metabolism, in conjunction 
with adipose tissue, hepatic, and systemic 
inflammation, are key factors involved in the 
development of insulin resistance, dyslipidemia, and 
other cardiometabolic risk factors associated with 
NAFLD.[5] A net retention of lipids within 
hepatocytes, mostly in the form of triglycerides, is a 
pre-requisite for the development of nonalcoholic fatty 
liver disease. The primary metabolic abnormalities 
leading to lipid accumulation is not well understood, 
but they could consist of alterations in the pathways of 
uptake, synthesis, degradation, or secretion in hepatic 
lipid metabolism resulting from insulin resistance.[6]  
 
MATERIALS AND METHODS 
The present study was conducted in Department of 
Biochemistry, Government Medical College, Patiala on 
80 cases (including controls) reporting in Department 
of Medicine, Rajindra Hospital, Patiala from March, 
2016 to November, 2016. The present hospital-based, 
observational, analytical and comparative study was 
subjected to statistically analysis. The study was 
approved by ethical committee of institute. 
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Sample  Collection 
Specimen collection – Blood sample, one in plain vial 
was collected under all aseptic conditions by 
venipuncture. The plain vial sample is allowed to clot 
and the serum was then separated by 
ultracentrifugation of the sample at room temperature. 
 
Investigations 
1. Determination of Triglycerides (TG)  
GPO - PAP Method. [7] 
Normal Range: 30-180 mg% 
2. Determination of Cholesterol: PAP Method. [8] 
Normal Range: 150-250 mg%  
3.  Determination of HDL Cholesterol
 Phosphotungstic Acid Method[9]  
Normal Range: 
 In males : 30-65 mg/dl 
 In females : 35-80 mg/dl  
4. Estimation of LDL-Cholesterol & VLDL 
Cholesterol 
Formula [10,11,12] 
VLDL-cholesterol = TG/5 
LDL-cholesterol = Total cholesterol - (TG/5 + HDL-
cholesterol)  
These were estimated from the primary measurements 
by using the empirical equation of Friedewald et al.[10] 
after determining total cholesterol and triglycerides by 
Allain et al[11] (1974) and McGowan et al[12] (1983).
 
Normal Range : 
VLDL-cholesterol- 20-40 mg/dl 
LDL-cholesterol- 114-153 mg/dl. 
 
RESULTS 
50 already diagnosed patients of NAFLD and 30 
controls were taken and following observations were 
made from the study. 
 
Table 1: Comparison of Serum Cholesterol Levels In NAFLD Patients and Control   Group 
Parameter Study Group Mean±S.D (mg%) p value Significance 
S. Cholesterol 
(N.V. 110-200 
mg%) 
Case 244.92±18.96 
0.00 HS 
Control 184.20±8.43 
 
The table above showed the comparison of S. 
Cholesterol Levels in NAFLD patients and control 
group. Mean±S.D. of case group was 244.92±18.96 
mg%, while Mean±S.D.  of control was 184.20±8.43 
mg%. The p value was 0.00. So there was highly 
significant difference between the case and control 
groups on account of NAFLD. 
 
Table-2: Comparison of Serum Triglycerides (Tg) Levels in NAFLD Patients and Control Group 
 
Above table showed the comparison of S. TG Levels in NAFLD patients and control group. Mean±S.D. of case 
group was 203.88±61.54 mg%, while Mean±S.D.  of control was 100.43±27.05 mg%. The p value was 0.00. So 
there was highly significant difference between the case and control groups on account of NAFLD. 
 
Table-3: Comparison of Serum HDL Levels in NAFLD Patients  and Control Group 
Parameter Study Group Mean±S.D (mg%) p value Significance 
S. TG 
(N.V. 30-180 mg%) 
Case 203.88±61.54 
0.00 HS 
Control 100.43±27.05 
Parameter Study Group Mean±S.D (mg%) p value Significance 
S. HDL 
(N.V. 38-75 mg%) 
Case 30.64±4.77 
0.00 HS 
Control 44.53±5.87 
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The table above showed the comparison of S. HDL Levels in NAFLD patients and control group. Mean±S.D. of 
case group was 30.64±4.77 mg%, while Mean ± S.D.  of control was 44.53±5.87 mg %. The p value was 0.00. So 
there was highly significant difference between the case and control groups on account of NAFLD. 
Table-4: Comparison of Serum LDL Levels in NAFLD Patients and Control Group 
 
The table above showed the comparison of S. LDL Levels in NAFLD patients and control group. Mean±S.D. of 
case group was 175.76±19.69 mg%, while Mean±S.D.  of control was 120.27±6.47 mg%. The p value was 0.00. 
So there was highly significant difference between the case and control groups on account of NAFLD. 
 
Table-5: Comparison of Serum VLDL Levels in NAFLD Patients and Control Group 
Parameter Study Group Mean±S.D (mg%) p value Significance 
S. VLDL 
(N.V. 20-40 mg%) 
Case 39.68±13.18 
0.00 HS 
Control 21.27±7.63 
 
The table above showed the comparison of S. VLDL Levels in NAFLD patients and control group. Mean±S.D. of 
case group was 39.68±13.18 mg%, while Mean±S.D.  of control was 21.27±7.63 mg%. The p value was 0.00. So 
there was highly significant difference between the case and control groups on account of NAFLD. 
 
DISCUSSION 
The study found a statistically significant change in 
lipid levels in patients of Non alcoholic fatty liver 
disease indicating hepatic steatosis. In the present 
study, increased levels of cholesterol, triacylglycerides, 
LDL, VLDL and decreased levels of HDL were found. 
The present study resembled who found higher levels 
of S. Cholesterol and S. Triglycerides in NAFLD 
patients.[12-15] Gaharwar et al[14] 2015, also found 
lower levels of S. HDL  and higher levels of S. LDL in 
NAFLD patients. The present study resembled 
Sharavnan et al[16] 2015, who found higher levels of 
S. VLDL in NAFLD patients. NAFLD was associated 
with increased SREBP-2 maturation, HMG CoA 
reductase (HMGCR) expression and decreased 
phosphorylation of HMGCR. Cholesterol synthesis 
was increased as measured by the circulating 
desmosterol:cholesterol ratio. miR-34a, a microRNA 
increased in NAFLD, inhibited sirtuin-1 with 
downstream dephosphorylation of AMP kinase and 
HMGCR.[17] The increased rates of fatty acid release 
into plasma and hepatic VLDL-TG secretion likely 
contribute to insulin resistance and hyper 
triglyceridemia that are commonly associated with 
NAFLD.[18] Low serum concentration of HDL-C and 
higher concentrations of triglycerides, the key features 
of insulin resistance dyslipidemia, were significantly 
different between patients with and without NAFLD. 
Higher fasting triglyceride levels and LDL particle 
concentrations were also significant associates of 
NAFLD.[19] 
 
CONCLUSION 
As NAFLD is rapidly becoming an important problem. 
Undiagnosed, this condition may progress silently and 
result in cirrhosis, portal hypertension, and liver-related 
death in early adulthood. The assessment of lipid 
profile for liver injury makes the development of non-
invasive, readily available, and easy-to-perform 
markers like Cholesterol, Triacylglycerides, HDL, 
VLDL, LDL a high priority for diagnostic purpose. So 
this study conveys the message that low fat diet, 
lifestyle modifications, exercises and yoga could be a 
potential tool to prevent the progression of NAFLD.  
 
 
Parameter Study Group Mean±S.D (mg%) p value Significance 
S. LDL 
(N.V. 114-153 mg%) 
Case 175.76±19.69 
0.00 HS 
Control 120.27±6.47 
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